Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cencora Inc.

295.04
+8.402.93%
Post-market: 295.040.00000.00%19:59 EDT
Volume:1.42M
Turnover:415.62M
Market Cap:57.19B
PE:34.36
High:295.19
Open:288.44
Low:287.40
Close:286.64
Loading ...

Why Cencora (COR) is a Top Value Stock for the Long-Term

Zacks
·
03 Feb

The Zacks Analyst Blog Highlights Amgen, Cencora, Humana and Ardent Health

Zacks
·
03 Feb

Cencora Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
01 Feb

Cardinal Health may raise prices to offset potential tariffs

Reuters
·
31 Jan

4 GARP Stocks That Investors Can Scoop Up for Maximum Returns

Zacks
·
30 Jan

Cardinal Health lifts 2025 profit forecast on specialty drugs demand

Reuters
·
30 Jan

Cencora (COR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zacks
·
29 Jan

Wells Fargo Adjusts Price Target on Cencora to $251 From $237, Keeps Equalweight Rating

MT Newswires Live
·
29 Jan

Cencora (COR) Gets a Hold from Wells Fargo

TIPRANKS
·
29 Jan

West Virginia top court urged to revive landmark opioid case against distributors

Reuters
·
29 Jan

Cencora, Inc. (COR) Hit a 52 Week High, Can the Run Continue?

Zacks
·
28 Jan

Morgan Stanley Sticks to Their Hold Rating for Cencora (COR)

TIPRANKS
·
28 Jan

Morgan Stanley Adjusts Cencora Price Target to $263 From $256, Maintains Equal Weight Rating

MT Newswires Live
·
28 Jan

Cencora Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
28 Jan

Will Cencora (COR) Beat Estimates Again in Its Next Earnings Report?

Zacks
·
28 Jan

Harrow Partners With Cencora to Launch Patient Support Program

MT Newswires Live
·
27 Jan

Harrow Partners with Cencora to Launch "Harrow Cares" Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

Business Wire
·
27 Jan

Cencora Is Maintained at Overweight by JP Morgan

Dow Jones
·
25 Jan

JPMorgan Raises Price Target on Cencora to $301 From $289, Maintains Overweight Rating

MT Newswires Live
·
24 Jan

The Zacks Analyst Blog Doximity, Omnicell, Embecta, Cencora and EDOC

Zacks
·
23 Jan